From Nastech, MDRNA Launches; Aims for Clinical Trials by Late Next Year | GenomeWeb

MDRNA has appeared on the horizon as another RNAi-focused company hoping to make good on the promise of using RNA interference to develop safe and effective RNA-based therapeutics. As part of a shift in business focus, the 55-person Bothell, Wash.-based company changed its name this summer from Nastech to MDRNA. Run by CEO Michael French, MDRNA's goal is to develop novel compounds and unique drug delivery techniques, aiming to get its lead candidate into phase I clinical trials by the end of 2009.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.